InDex Pharmaceuticals announces expected cash balance per March 31, 2024

Contributed by: PR Newswire

Tags

InDex-Pharmaceuticals

More Like This

InDex Pharmaceuticals is attending the UEGW 2023 congress

InDex Pharmaceuticals announces that all patients needed for the cobitolimod dose selection milestone have completed Induction Study 1 of the phase III program CONCLUDE

InDex Pharmaceuticals discontinues cobitolimod phase III program

InDex Pharmaceuticals has been granted a new patent for cobitolimod in South Korea

Orexo Interim Report Q4 2023, incl. Full Year Report

Calliditas Interim Report January to June 2024

Orexo Q1 2024 Interim Report

Hansa Biopharma interim report January-March 2024